CEO turned informant: How the FDA built a case against executives promising cheap medications
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
The federal case against an alleged illegal prescription drug operation and its two top leaders earlier this month features a notable informant: the CEO of a peer company that authorities say was committing the same import violations.
John Thomas Howard, treasurer and director of a Canadian healthcare company called CANARX, was arrested in the tunnel connecting Detroit and Canada on Nov. 8 and charged with smuggling, conspiracy and importing a misbranded drug for patient use in the United States. His brother and the president of the company, Bob Howard, is wanted on similar charges and was still being sought as of last week, according to court records.
The charges mark the first criminal case by U.S. authorities against a company that's part of a cottage industry known as alternative funding programs, or AFPs, that promise to lower or eliminate high prescription drug costs for Americans.
The cheaper medications are typically sourced from international markets, a business model that the Food and Drug Administration and Department of Homeland Security say is illegal and can put patients' health at risk.
At issue is the unregulated nature of drugs intended for foreign markets and, in some cases, the risk of counterfeit products. And while AFPs generally argue that the importation of medication is allowable under U.S. law by individuals for personal use, authorities contend the operations go too far.
CANARX, based in Windsor, Ontario, was established in 2002 and was featured in a CNBC investigation into the booming AFP industry.
Joseph Morris, general counsel for CANARX, told CNBC last year that the business was operating legally and was confident in the safety of the prescriptions it provided. Last week, Morris told CNBC that the Howard brothers "deny all the charges against them, will defend vigorously, and expect to be vindicated in court."
The FDA's case against CANARX started with a tip about a similar healthcare operation called ScriptSourcing. It is detailed in a 35-page affidavit — dated Oct. 29 and unsealed last week — written by Dustin Dobbs, special agent with the FDA's Office of Criminal Investigations.
Based in Bonita Springs, Florida, ScriptSourcing marketed its international prescription program to self-funded employer health plans. Founder and CEO Gary Becker was described on the company's website as a "health insurance and risk management consultant for more than 30 years."
ScriptSourcing had been on the FDA's radar since at least 2022 for potential drug import violations, according to the affidavit. In August 2025, Dobbs, posing as someone interested in the AFP business, emailed ScriptSourcing and asked if the company was FDA-compliant.
A ScriptSourcing employee in responses to Dobbs said the company was FDA-compliant and that it had more than 2,000 name brand specialty medications and worked with more than 3,000 self-funded health plans.
However, that same year, the agency learned of two alleged incidents in which medications from ScriptSourcing's international drug import program had harmed patients, according to Dobbs' affidavit. One patient had been hospitalized due to a small bowel obstruction after she used misbranded Mounjaro sourced by the company via a Canadian pharmacy, and another was allegedly seriously injured after receiving a counterfeit medication.
Facing scrutiny from the FDA, ScriptSourcing CEO Becker turned on the Howard brothers of CANARX.
By May 2026, Becker had become a cooperating witness for the government in its investigation into the Canadian firm, Dobbs wrote. Becker told the FDA that he had done business with CANARX on drug importation and that the company had given him a "road map" on how to operate, according to the affidavit.
ScriptSourcing provided the FDA with a spreadsheet of financial transactions with CANARX between 2021 and 2026. It showed approximately 16,549 prescription drugs have been dispensed, the affidavit said.
Then, in several recorded phone calls between June and July 2026, Becker discussed the foreign importations with the Howard brothers.
The phone calls "show that John Howard was aware of the routes for importation of drugs from Canada into the United States and has tried to mold them to fit [CANARX's] illegal drug importation program," Dobbs wrote in the affidavit. "These phone calls also show that John Howard and Bob Howard were aware that these drugs were not allowed to enter into the United States legally."
Among the shipments en route or being prepared by CANARX at the time the information was provided was a package that contained Neupro, an FDA-regulated drug for the treatment of Parkinson's disease and restless legs syndrome.
The FDA did not respond to a request for comment from CNBC on the details in the affidavit.
Gary Becker's attorney, George Karavetsos, declined to comment when reached by CNBC, but confirmed on Monday that ScriptSourcing was no longer in business.
The AFP business model was at the center of a civil lawsuit originally filed by Gilead Sciences in December 2024 that alleged several companies, including CANARX, illegally imported its HIV drug Biktarvy. CANARX has not responded to Gilead's allegations.
Gilead said in a statement to CNBC last week in response to charges against the Howard brothers that it "welcomed the government's efforts to hold accountable those whose conduct may put patients at risk."
"Pharmaceuticals manufactured for foreign markets are almost always considered unapproved and misbranded drugs under U.S. law, whether counterfeit or even if made by the same manufacturer that produced the version sold in the United States," Dobbs wrote in his affidavit.
— CNBC's Melissa Lee and Paige Tortorelli contributed to this report.
Not cross-checked yet
Only CNBC reports this story so far. We show it as a single source until another newsroom confirms it.
- CNBC18 Nov, 22:07
| Publisher CNBC (reference tier) | +82 |
| Detailed summary | +2 |
| Total | 84 |
Method: reports are grouped by the words of their headline and summary; each newsroom counts once; figures are read from the reports as published. Nothing here is written by an AI.
